Literature DB >> 11827515

Arg(362) and Tyr(365) of the botulinum neurotoxin type a light chain are involved in transition state stabilization.

Thomas Binz1, Steffen Bade, Andreas Rummel, Astrid Kollewe, Jürgen Alves.   

Abstract

The botulinum neurotoxin type A (BoNT/A) light chain (LC) acts as zinc endopeptidase. The X-ray structure of the toxin demonstrated that Zn(2+) is coordinated by His(222) and His(226) of the Zn(2+) binding motif HisGluXXHis and Glu(261), whereas Glu(223) coordinates the water molecule required for hydrolysis as the fourth ligand. Recent analysis of a cocrystal of the BoNT/B LC and its substrate synaptobrevin 2 suggested that Arg(362) and Tyr(365) of the homologous BoNT/A may be directly involved in catalysis. Their role and that of Glu(350) which is also found in the vicinity to the active site were analyzed by site-directed mutagenesis. Various replacements of Arg(362) and substitution of Tyr(365) with Phe resulted in 79- and 34-fold lower k(cat)/K(m) values, respectively. These changes were provoked by decreased catalytic rates (k(cat)) and not by alterations of ground state substrate binding as evidenced by largely unchanged K(d) and K(m) values. None of these mutations affected the overall secondary structure or zinc content of the LC. These findings suggest that the guanidino group of Arg(362) and the hydroxyl group of Tyr(365) together accomplish transition state stabilization as was proposed for thermolysin, being the prototypical member of the gluzincin superfamily of metalloproteases. Mutation of Glu(350) dramatically diminished the hydrolytic activity which must partly be attributed to an altered active site fine structure as demonstrated by an increased sensitivity toward heat-induced denaturing and a lower Zn(2+) binding affinity. Glu(350) apparently occupies a central position in the active site and presumably positions His(222) and Arg(362).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11827515     DOI: 10.1021/bi0157969

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  35 in total

1.  In Vivo Toxicity and Immunological Characterization of Detoxified Recombinant Botulinum Neurotoxin Type A.

Authors:  Easwaran Ravichandran; Pavithra Janardhanan; Kruti Patel; Stephen Riding; Shuowei Cai; Bal Ram Singh
Journal:  Pharm Res       Date:  2015-11-03       Impact factor: 4.200

2.  The closed structure of presequence protease PreP forms a unique 10,000 Angstroms3 chamber for proteolysis.

Authors:  Kenneth A Johnson; Shashi Bhushan; Annelie Ståhl; B Martin Hallberg; Anne Frohn; Elzbieta Glaser; Therese Eneqvist
Journal:  EMBO J       Date:  2006-04-06       Impact factor: 11.598

3.  Recombinant holotoxoid vaccine against botulism.

Authors:  Christina L Pier; William H Tepp; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri; Michael R Baldwin
Journal:  Infect Immun       Date:  2007-10-29       Impact factor: 3.441

Review 4.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

5.  Structural insight into exosite binding and discovery of novel exosite inhibitors of botulinum neurotoxin serotype A through in silico screening.

Authors:  Xin Hu; Patricia M Legler; Noel Southall; David J Maloney; Anton Simeonov; Ajit Jadhav
Journal:  J Comput Aided Mol Des       Date:  2014-06-24       Impact factor: 3.686

6.  Association of botulinum neurotoxin serotype A light chain with plasma membrane-bound SNAP-25.

Authors:  Sheng Chen; Joseph T Barbieri
Journal:  J Biol Chem       Date:  2011-03-04       Impact factor: 5.157

7.  The structure of the tetanus toxin reveals pH-mediated domain dynamics.

Authors:  Geoffrey Masuyer; Julian Conrad; Pål Stenmark
Journal:  EMBO Rep       Date:  2017-06-23       Impact factor: 8.807

8.  Identification of the synaptic vesicle glycoprotein 2 receptor binding site in botulinum neurotoxin A.

Authors:  Jasmin Strotmeier; Stefan Mahrhold; Nadja Krez; Constantin Janzen; Jianlong Lou; James D Marks; Thomas Binz; Andreas Rummel
Journal:  FEBS Lett       Date:  2014-02-25       Impact factor: 4.124

9.  Iterative structure-based peptide-like inhibitor design against the botulinum neurotoxin serotype A.

Authors:  Jorge E Zuniga; Jared T Hammill; Omri Drory; Jonathan E Nuss; James C Burnett; Rick Gussio; Peter Wipf; Sina Bavari; Axel T Brunger
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

10.  Light chain separated from the rest of the type a botulinum neurotoxin molecule is the most catalytically active form.

Authors:  Nizamettin Gul; Leonard A Smith; S Ashraf Ahmed
Journal:  PLoS One       Date:  2010-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.